Abstract
Since deleterious effects of m-CPP, the primary catabolic metabolite of trazodone, were last reviewed 2 years ago, research data continue to accrue showing that clinically significant levels of m-CPP (a) are generated in patients using trazodone for sleep and (b) are present 24 h a day and (c) have potentially serious ill effects. This commentary argues that the documented potential for harm and multiple risks of m-CPP outweigh potential benefits of trazodone, given the development and marketing of many safer alternatives since trazodone's introduction in the 1980s.
MeSH terms
-
Animals
-
Antidepressive Agents, Second-Generation / adverse effects*
-
Antidepressive Agents, Second-Generation / pharmacokinetics
-
Antidepressive Agents, Second-Generation / therapeutic use
-
Anxiety / chemically induced
-
Anxiety / physiopathology
-
Biotransformation
-
Brain / drug effects
-
Brain / physiopathology
-
Dose-Response Relationship, Drug
-
Drug-Related Side Effects and Adverse Reactions
-
Humans
-
Mice
-
Panic / drug effects
-
Panic / physiology
-
Piperazines / adverse effects
-
Piperazines / blood*
-
Receptor, Serotonin, 5-HT2B / drug effects
-
Receptor, Serotonin, 5-HT2B / physiology
-
Receptor, Serotonin, 5-HT2C / drug effects
-
Receptor, Serotonin, 5-HT2C / physiology
-
Risk Factors
-
Serotonin Receptor Agonists / adverse effects
-
Serotonin Receptor Agonists / blood*
-
Structure-Activity Relationship
-
Trazodone / adverse effects*
-
Trazodone / pharmacokinetics
-
Trazodone / therapeutic use
Substances
-
Antidepressive Agents, Second-Generation
-
Piperazines
-
Receptor, Serotonin, 5-HT2B
-
Receptor, Serotonin, 5-HT2C
-
Serotonin Receptor Agonists
-
1-(3-chlorophenyl)piperazine
-
Trazodone